Xenon Pharmaceuticals Inc. (XENE) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Xenon Pharmaceuticals Inc. (XENE) surged +3.30% to $37.54 as options desks priced 56% call premium vs. 44% put protection around the $37 max-pain magnet. Solid 41% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercia
XEN1701 achieved target profile, including desired NaV1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effectsXEN1120 ach
Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need,
Positive trial data for Rapport’s lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +7.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XENE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XENE. Explore sector supply chains on /butterfly.
Why XENE Stock surged +3.30% Today — RQD Quant Desk Flash. Solid 41% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.